| Literature DB >> 36127323 |
Martin Hasselblatt1, Jasmin Bartl2,3,4,5, Marc Remke6,7,8, Lena Blümel9,10,11, Nan Qin2,3,4, Johannes Berlandi1, Eunice Paisana12, Rita Cascão12, Carlos Custódia12, David Pauck2,3,4, Daniel Picard2,3,4, Maike Langini3,13, Kai Stühler13,14, Frauke-Dorothee Meyer2,3,4, Sarah Göbbels2,3,4, Bastian Malzkorn4, Max C Liebau15,16, João T Barata12, Astrid Jeibmann1, Kornelius Kerl17, Serap Erkek18,19, Marcel Kool18,19,20, Stefan M Pfister18,19,21, Pascal D Johann18,19,21,22, Michael C Frühwald22, Arndt Borkhardt2,3, Guido Reifenberger3,4, Claudia C Faria12,23, Ute Fischer2,3.
Abstract
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant brain tumor in infants that is characterized by loss of nuclear expression of SMARCB1 or SMARCA4 proteins. Recent studies show that AT/RTs comprise three molecular subgroups, namely AT/RT-TYR, AT/RT-MYC and AT/RT-SHH. The subgroups show distinct expression patterns of genes involved in ciliogenesis, however, little is known about the functional roles of primary cilia in the biology of AT/RT. Here, we show that primary cilia are present across all AT/RT subgroups with specific enrichment in AT/RT-TYR patient samples. Furthermore, we demonstrate that primary ciliogenesis contributes to AT/RT biology in vitro and in vivo. Specifically, we observed a significant decrease in proliferation and clonogenicity following disruption of primary ciliogenesis in AT/RT cell line models. Additionally, apoptosis was significantly increased via the induction of STAT1 and DR5 signaling, as detected by proteogenomic profiling. In a Drosophila model of SMARCB1 deficiency, concomitant knockdown of several cilia-associated genes resulted in a substantial shift of the lethal phenotype with more than 20% of flies reaching adulthood. We also found significantly extended survival in an orthotopic xenograft mouse model of AT/RT upon disruption of primary ciliogenesis. Taken together, our findings indicate that primary ciliogenesis or its downstream signaling contributes to the aggressiveness of AT/RT and, therefore, may constitute a novel therapeutic target.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36127323 PMCID: PMC9489777 DOI: 10.1038/s41419-022-05243-4
Source DB: PubMed Journal: Cell Death Dis Impact factor: 9.685